MYO Earnings Prediction
The chart below shows how MYO performed 10 days before and after its earnings report, based on data from the past quarters. Typically, MYO sees a +1.71% change in stock price 10 days leading up to the earnings, and a -0.22% change 10 days following the report. On the earnings day itself, the stock moves by +1.42%. This data can give you a slight idea of what to expect for the next quarter's release.
MYO Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
--
--
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
--
--
--
No Data Available
MYO Earnings Analysis
Myomo Inc Corporation (MYO.A) Earnings Conference Call
Positive
Earnings Surprise Achieved: Myomo, Inc. beats earnings expectations with reported EPS of $-0.01, exceeding expectations of $-0.02.
Transformational Year Achievements: 2024 was a transformational year for Myomo, with record financial and operating results driven by Medicare Part B coverage.
Q4 Revenue Surge: Revenues for Q4 were $12.1 million, more than double Q4 '23, and full-year revenues reached $32.6 million, a 69% increase from the previous year.
Revenue Unit Doubling: Delivered 220 revenue units in Q4, double the volume from Q4 '23, and over 600 devices for the year, serving more than 3,000 patients.
Patient Pipeline Expansion: Added 657 medically-qualified candidates to the patient pipeline in Q4, ending the year with nearly 1,400 patients in the process of obtaining MyoPro.
Record MyoPros Orders: Achieved a record 233 MyoPros authorized and ordered in Q4, with over 140 covered by Medicare.
O&P Revenue Surge: O&P revenue grew to $600,000 in Q4, up 94% sequentially, as more clinics began the process of becoming MyoPro centers of excellence.
Strong Global Demand: International business generated over $1 million in revenue in Q4 and over $4 million for the full year, indicating strong global demand.
Positive Adjusted EBITDA Achievement: Achieved positive adjusted EBITDA for the first time in company history, with $200,000 in Q4, a significant improvement from the previous year.
Q1 and Full-Year Revenue Guidance: Expecting Q1 2025 revenue between $9 million and $9.5 million, reflecting a 140% to 153% increase over the prior year, and full-year guidance of $50 million to $53 million, representing growth of 54% to 66% over 2024.
Negative
Earnings Beat, Net Loss: Despite beating earnings expectations with an EPS of $-0.01, the company still reported a net loss of $300,000 for Q4 2024, indicating ongoing financial challenges.
Rising Operating Expenses: Operating expenses increased by 60% year-over-year to $8.9 million, driven by higher headcount and R&D expenses, which could strain future profitability.
Medicare Advantage Challenges: The company continues to face challenges with Medicare Advantage, where many patients are denied coverage for MyoPro, reflecting broader issues in the healthcare reimbursement landscape.
Medicare Revenue Challenges: While revenue from Medicare Part B patients is growing, the slow appeals process for Medicare Advantage denials remains a significant hurdle, impacting cash flow and revenue recognition.
Negative Cash Flow Outlook: The company anticipates negative cash flows in the first three quarters of 2025, which could affect operational stability and growth plans during that period.
MYO FAQs
How does MYO typically perform around its earnings report dates?
Is Myomo Inc (MYO) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
MYO Earning Call Sentiment
Myomo, Inc. (AMEX:MYO) Q4 2024 Earnings Call Transcript
MYO.A
40.77%Positive
The earnings call reveals strong financial performance with record revenues, improved margins, and narrowed losses. Despite some challenges like insurance denials and supply chain issues, the company shows robust growth potential, particularly in the O&P channel. The Q&A indicates continued growth and efficiency in operations, although some uncertainty remains. Overall, the positive financial results and raised guidance suggest a favorable short-term stock price movement.
